WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406406
Description: SU11271 is a potent c-MET inhibitor with potential anticancer activity.
MedKoo Cat#: 406406
Chemical Formula: C29H31N5O4S
Exact Mass: 545.20968
Molecular Weight: 545.65
Elemental Analysis: C, 63.83; H, 5.73; N, 12.83; O, 11.73; S, 5.88
SU11271 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to firstname.lastname@example.org to inquire quote.
Synonym: SU11271; SU11271; SU 11271.
IUPAC/Chemical Name: (Z)-3-((3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl)methylene)-5-(indolin-1-ylsulfonyl)indolin-2-one
InChi Key: MHTSQKQLTZCFPE-QJOMJCCJSA-N
InChi Code: InChI=1S/C29H31N5O4S/c1-18-25(30-19(2)27(18)29(36)33-14-12-32(3)13-15-33)17-23-22-16-21(8-9-24(22)31-28(23)35)39(37,38)34-11-10-20-6-4-5-7-26(20)34/h4-9,16-17,30H,10-15H2,1-3H3,(H,31,35)/b23-17-
SMILES Code: O=C1NC2=C(C=C(S(=O)(N3CCC4=C3C=CC=C4)=O)C=C2)/C1=C/C5=C(C)C(C(N6CCN(C)CC6)=O)=C(C)N5
The following data is based on the product molecular weight 545.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. La Monica, Silvia; Caffarra, Cristina; Saccani, Francesca; Galvani, Elena; Galetti, Maricla; Fumarola, Claudia; Bonelli, Mara; Cavazzoni, Andrea; Cretella, Daniele; Sirangelo, Rita; et al. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One (2013), 8(10), e78656.
2. Golub, Todd; Straussman, Ravid. Methods of treating cancer using a chemotherapeutic agent with an agent that blocks the activity of hepatocyte growth factor or its cognate receptor c-MET. PCT Int. Appl. (2012), WO 2012178038 A1 20121227
3. Wang, Xueyan; Le, Phuong; Liang, Congxin; Chan, Julie; Kiewlich, David; Miller, Todd; Harris, Dave; Sun, Li; Rice, Audie; Vasile, Stefan; et al. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Molecular Cancer Therapeutics (2003), 2(11), 1085-1092.